NuvoAir is a digital health company on a mission to improve the lives of millions of people suffering from respiratory conditions.
NuvoAir envisions a world where all people have the opportunity to manage and achieve better respiratory health.
NuvoAir was founded in 2016 in Stockholm, Sweden, by Lorenzo Consoli. The company is headquartered in Boston, MA, with an office in Stockholm, Sweden.
NuvoAir combines a patient app with connected devices, self-management content, care coordination services, and a provider portal to support members. The platform's technologies include a Bluetooth-enabled spirometer to remotely monitor lung function; a sensor that attaches to asthma and COPD inhalers; and Fitbit integration
NuvoAir Home currently supports thousands of patients worldwide with COPD, cystic fibrosis, severe asthma, IPF, ALS, and muscular dystrophy. NuvoAir's decentralized clinical trial solution has been used in over 30 studies globally across all phases of drug development.
NuvoAir has partnered with providers across the U.S., U.K. and Europe, including Harvard Boston Children's Hospital, New Hampshire's Dartmouth-Hitchcock Medical Center, Royal Brompton Hospital, King's College Hospital in London, as well as pharmaceutical giants Roche, Regeneron and Novartis.
NuvoAir is backed by AlbionVC, Hikma Ventures, Spiltan, Industrifonden, Novartis Pharma AG, Amino Collective, and others. The company raised $11M in a latest financing on Jan 19, 2022. This is an extension of the $12M Series A round raised in Jun 2021, bringing the round total to $23M. The additional investment brings NuvoAir's total funding to $28.2M to date.